Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).
作者信息
Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure Á, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez C A, Trigo J M, Germà J R, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J
机构信息
Centro Oncológico MD Anderson España, Madrid.
Hospital Virgen de la Victoria, Málaga.
出版信息
Ann Oncol. 2010 Feb;21(2):195-198. doi: 10.1093/annonc/mdp595.
Abstract
摘要
相似文献
1
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).口服药物治疗癌症：西班牙医学肿瘤学会（SEOM）的立场声明。
Ann Oncol. 2010 Feb;21(2):195-198. doi: 10.1093/annonc/mdp595.
2
The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.西班牙医学肿瘤学会（SEOM）临床肿瘤学指南的相关性。
Clin Transl Oncol. 2010 Nov;12(11):707-8. doi: 10.1007/s12094-010-0582-9.
3
Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain.西班牙肿瘤医学学会（SEOM）关于西班牙肿瘤药物和预测性生物标志物可及性的研究。
Clin Transl Oncol. 2020 Dec;22(12):2253-2263. doi: 10.1007/s12094-020-02366-y. Epub 2020 Jun 12.
4
Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of Urology.口服药物（阿比特龙和抗血管生成药物）治疗前列腺癌和肾癌：西班牙泌尿外科学会的立场声明
Actas Urol Esp. 2013 Jun;37(6):321-3. doi: 10.1016/j.acuro.2013.04.001. Epub 2013 May 23.
5
Is it the right time for multidisciplinarity in Spanish clinical oncology? I think so.西班牙临床肿瘤学的多学科合作时机是否恰当？我认为是恰当的。
Clin Transl Oncol. 2010 May;12(5):387-8. doi: 10.1007/s12094-010-0522-8.
6
SEOM clinical guidelines for the adjuvant treatment of colorectal cancer.SEOM 结直肠癌辅助治疗临床指南。
Clin Transl Oncol. 2010 Nov;12(11):724-8. doi: 10.1007/s12094-010-0586-5.
7
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.公平性、障碍与癌症差异：西班牙医学肿瘤学会关于西班牙各地区肿瘤药物可及性的研究
Clin Transl Oncol. 2017 Mar;19(3):341-356. doi: 10.1007/s12094-016-1535-8. Epub 2016 Aug 25.
8
Interview with Dr. Ramón Colomer Bosch, President of the Spanish Society of Medical Oncology (SEOM) by Enrique Garcia Jorda.恩里克·加西亚·霍尔达对西班牙医学肿瘤学会（SEOM）主席拉蒙·科洛默·博施博士的采访。
Clin Transl Oncol. 2008 Jun;10(6):310-2. doi: 10.1007/s12094-008-0205-x.
9
TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM).TESEO，西班牙医学肿瘤学会（SEOM）的癌症相关血栓形成登记处。
Clin Transl Oncol. 2020 Aug;22(8):1423-1424. doi: 10.1007/s12094-019-02265-x. Epub 2019 Dec 23.
10
Skin Cancer and the Dermatologist: Reflections on the Position Taken by the Spanish Society of Medical Oncology (SEOM).皮肤癌与皮肤科医生：关于西班牙医学肿瘤学会（SEOM）立场的思考
Actas Dermosifiliogr. 2017 Oct;108(8):704-707. doi: 10.1016/j.ad.2017.06.003. Epub 2017 Jul 10.
引用本文的文献
1
Maximum tolerated dose and toxicity evaluation of orally administered docetaxel granule in mice.多西他赛颗粒口服给药在小鼠中的最大耐受剂量及毒性评价
Toxicol Rep. 2024 Apr 5;12:430-435. doi: 10.1016/j.toxrep.2024.04.001. eCollection 2024 Jun.
2
Computational identification of potential inhibitors targeting in colorectal cancer.结直肠癌中潜在靶向抑制剂的计算鉴定
Front Chem. 2023 Nov 30;11:1264808. doi: 10.3389/fchem.2023.1264808. eCollection 2023.
3
Trends and prescribing patterns of oral anti-neoplastic drugs: a retrospective longitudinal study.口服抗肿瘤药物的趋势和处方模式：一项回顾性纵向研究。
Front Public Health. 2023 Nov 23;11:1294126. doi: 10.3389/fpubh.2023.1294126. eCollection 2023.
4
Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence.乳腺癌口腔溶瘤药物的进展及促进依从性的建议
J Adv Pract Oncol. 2020 Jan-Feb;11(1):83-96. doi: 10.6004/jadpro.2020.11.1.5. Epub 2020 Jan 1.
5
Fatigue in patients on oral targeted or chemotherapy for cancer and associations with anxiety, depression, and quality of life.癌症患者口服靶向或化疗药物后的疲劳及其与焦虑、抑郁和生活质量的关系。
Palliat Support Care. 2020 Apr;18(2):141-147. doi: 10.1017/S147895151900066X.
6
Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy.一种c-MET酪氨酸激酶抑制剂与CDK 4/6抑制剂联合药物疗法的单次口服剂量急性和亚急性毒性
Am J Cancer Res. 2018 Jan 1;8(1):183-191. eCollection 2018.
7
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.老年癌症患者中特定抗癌药物的药代动力学：聚焦乳腺癌
Cancers (Basel). 2016 Jan 2;8(1):6. doi: 10.3390/cancers8010006.
8
Oral chemotherapy prescription safety practices in Europe.
Int J Clin Pharm. 2014 Oct;36(5):863-4. doi: 10.1007/s11096-014-0002-2. Epub 2014 Sep 7.
9
The next generation of radiation oncologists: Challenges and perspectives.下一代放射肿瘤学家：挑战与展望。
Rep Pract Oncol Radiother. 2012 Sep 25;17(5):243-5. doi: 10.1016/j.rpor.2012.08.004. eCollection 2012 Sep.
10
The prescription of oral anticancer drugs: Another perspective.口服抗癌药物的处方：另一种视角
Rep Pract Oncol Radiother. 2012 Nov 8;17(6):295-7. doi: 10.1016/j.rpor.2012.10.005. eCollection 2012.
本文引用的文献
1
Alternate endpoints for screening phase II studies.筛选性II期研究的替代终点。
Clin Cancer Res. 2009 Mar 15;15(6):1873-82. doi: 10.1158/1078-0432.CCR-08-2034. Epub 2009 Mar 10.
2
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.《2008年临床癌症进展：癌症治疗、预防及筛查的重大研究进展——美国临床肿瘤学会报告》
J Clin Oncol. 2009 Feb 10;27(5):812-26. doi: 10.1200/JCO.2008.21.2134. Epub 2008 Dec 22.
3
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
4
Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC.一项关于晚期非小细胞肺癌患者对口服或静脉注射长春瑞滨联合卡铂治疗的偏好的随机交叉研究。
Lung Cancer. 2008 Oct;62(1):85-91. doi: 10.1016/j.lungcan.2008.02.009. Epub 2008 Mar 26.
5
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.《2007年临床癌症进展：癌症治疗、预防及筛查的重大研究进展——美国临床肿瘤学会报告》
J Clin Oncol. 2008 Jan 10;26(2):313-25. doi: 10.1200/JCO.2007.15.4088. Epub 2007 Dec 17.
6
The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO).肿瘤学中药物的超说明书用药：欧洲医学肿瘤学会（ESMO）立场文件
Ann Oncol. 2007 Dec;18(12):1923-5. doi: 10.1093/annonc/mdm517.
7
National integration of European standards.
Ann Oncol. 2007 Jun;18(6):969-70. doi: 10.1093/annonc/mdm122.
8
We should desist using RECIST, at least in GIST.我们应该停止使用RECIST，至少在胃肠道间质瘤（GIST）中应如此。
J Clin Oncol. 2007 May 1;25(13):1760-4. doi: 10.1200/JCO.2006.07.3411.
9
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.2006年临床癌症进展：癌症治疗、预防及筛查方面的重大研究进展——美国临床肿瘤学会报告
J Clin Oncol. 2007 Jan 1;25(1):146-62. doi: 10.1200/JCO.2006.09.7030. Epub 2006 Dec 8.
10
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.《2005年临床癌症进展：癌症治疗、预防及筛查的重大研究进展——美国临床肿瘤学会报告》
J Clin Oncol. 2006 Jan 1;24(1):190-205. doi: 10.1200/JCO.2005.04.8678. Epub 2005 Dec 2.
Zotero 插件